688321 微芯生物
已收盘 07-23 15:00:01
资讯
新帖
简况
微芯生物最新公告：西达本胺治疗结直肠癌获得药物临床试验批准通知书
证券之星 · 32分钟前
微芯生物最新公告：西达本胺治疗结直肠癌获得药物临床试验批准通知书
微芯生物(688321.SH)：西达本胺治疗结直肠癌获得药物临床试验批准通知书
智通财经 · 50分钟前
微芯生物(688321.SH)：西达本胺治疗结直肠癌获得药物临床试验批准通知书
微芯生物(688321)：原创新药多适应症拓展 有望开启国际化新征程
太平洋证券股份... · 00:00
微芯生物(688321)：原创新药多适应症拓展 有望开启国际化新征程
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.27%
自选股智能写手 · 07-22 09:42
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.27%
微芯生物(688321.SH)：西格列他钠联合二甲双胍治疗2型糖尿病适应症获批
智通财经 · 07-19
微芯生物(688321.SH)：西格列他钠联合二甲双胍治疗2型糖尿病适应症获批
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.07%
自选股智能写手 · 07-18
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.07%
非酒精性脂肪性肝炎(NASH)概念盘中跳水，康弘药业跌5.10%
自选股智能写手 · 07-15
非酒精性脂肪性肝炎(NASH)概念盘中跳水，康弘药业跌5.10%
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨3.66%
自选股智能写手 · 07-11
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨3.66%
北向资金7月10日净卖出微芯生物3.58万股 连续3日减持
自选股智能写手 · 07-11
北向资金7月10日净卖出微芯生物3.58万股 连续3日减持
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.86%
自选股智能写手 · 07-08
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.86%
微芯生物（688321）7月5日主力资金净买入159.07万元
证券之星 · 07-06
微芯生物（688321）7月5日主力资金净买入159.07万元
7月5日微芯生物涨5.35%，工银优选对冲灵活配置混合发起A基金重仓该股
证券之星 · 07-05
7月5日微芯生物涨5.35%，工银优选对冲灵活配置混合发起A基金重仓该股
微芯生物：西奥罗尼III期试验已结束，目前正在推进Pre-NDA沟通工作
每日经济新闻 · 07-05
微芯生物：西奥罗尼III期试验已结束，目前正在推进Pre-NDA沟通工作
微芯生物07月04日主力资金流出10万元 连续7日减仓
自选股智能写手 · 07-04
微芯生物07月04日主力资金流出10万元 连续7日减仓
微芯生物：第二季度“微芯转债”转股39股，累计转股4243股
每日经济新闻 · 07-01
微芯生物：第二季度“微芯转债”转股39股，累计转股4243股
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌1.36%
自选股智能写手 · 07-01
非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌1.36%
微芯生物6月28日转融通出借成交6100股
金融界 · 07-01
微芯生物6月28日转融通出借成交6100股
微芯生物新提交1件商标注册申请
证券之星 · 06-29
微芯生物新提交1件商标注册申请
深圳微芯生物科技股份有限公司注册资本(金)变更发生变更
金融界 · 06-29
深圳微芯生物科技股份有限公司注册资本(金)变更发生变更
微芯生物公布国际专利申请：“一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用”
证券之星 · 06-29
微芯生物公布国际专利申请：“一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用”
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":16.82,"timestamp":1721718001000,"preClose":17.55,"halted":0,"volume":2099325,"delay":0,"floatShares":408000000,"shares":408000000,"eps":0.2527,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.73,"latestTime":"07-23 15:00:01","open":17.52,"high":17.57,"low":16.8,"amount":35903500,"amplitude":0.0439,"askPrice":16.83,"askSize":11,"bidPrice":16.82,"bidSize":439,"shortable":0,"etf":0,"ttmEps":0.2527,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721784600000},"adr":0,"adjPreClose":17.55,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":19.31,"lowLimit":15.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407795845,"pbRate":4.38,"roa":"--","roe":"--","epsLYR":0.2176,"committee":-0.254391,"marketValue":6859000000,"floatMarketCap":6859000000,"peRate":66.561139,"changeRate":-0.0416,"turnoverRate":0.0051,"status":1,"afterMarket":{"amount":0,"volume":0,"close":16.82,"buyVolume":0,"sellVolume":0,"time":1721720037153,"indexStatus":"已收盘 07-23 15:30:00","preClose":17.55}},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2453815380","title":"微芯生物最新公告：西达本胺治疗结直肠癌获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453815380","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453815380?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:00","pubTimestamp":1721728800,"startTime":"0","endTime":"0","summary":"微芯生物公告，近日收到国家药监局签发的境内生产药品注册临床试验的《药物临床试验批准通知书》，西达本胺联合信迪利单抗和贝伐珠单抗治疗≥2线标准治疗失败的晚期微卫星稳定或错配修复完整（MSS/pMMR）型结直肠癌的随机、开放性、对照、多中心、Ⅲ期临床试验申请获得批准。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300034639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0239","03347","688321","BK1576","BK1583"],"gpt_icon":0},{"id":"2453132086","title":"微芯生物(688321.SH)：西达本胺治疗结直肠癌获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453132086","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453132086?lang=zh_cn&edition=full","pubTime":"2024-07-23 17:42","pubTimestamp":1721727736,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司近日收到国家药品监督管理局签发的境内生产药品注册临床试验的《药物临床试验批准通知书》，西达本胺联合信迪利单抗和贝伐珠单抗治疗≥2线标准治疗失败的晚期微卫星稳定或错配修复完整(MSS/pMMR)型结直肠癌的随机、开放性、对照、多中心、Ⅲ期临床试验申请获得批准。根据国家药品注册相关的法律法规要求，药品在获得临床试验申请批准后，尚需开展临床试验，并经国家药监局批准后方可生产上市。本临床试验申请获得批准事项对公司近期业绩不会产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688321","BK1576","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2453772690","title":"微芯生物(688321)：原创新药多适应症拓展 有望开启国际化新征程","url":"https://stock-news.laohu8.com/highlight/detail?id=2453772690","media":"太平洋证券股份...","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453772690?lang=zh_cn&edition=full","pubTime":"2024-07-23 00:00","pubTimestamp":1721664000,"startTime":"0","endTime":"0","summary":"我们假设患者人群2.4 万人，渗透率20%，单患者治疗费用12 万元/年，用药时长2 年，西达本胺新增DLBCL 适应症销售峰值有望达11.7 亿元。根据GLOBOCAN 统计数据，2022 年中国结直肠癌发病人数和死亡人数在全部恶性肿瘤中分别位居第二位和第四位。根据2023 年年报数据，西格列他钠已准入医院1052 家，覆盖全国1850 家药店。风险提示创新药研发不及预期风险；新产品放量不及预期风险；医保支付政策调整带来的风险；地缘政治风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231317059ee13fc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231317059ee13fc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688321","BK0239"],"gpt_icon":0},{"id":"2453788579","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453788579","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453788579?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:42","pubTimestamp":1721612544,"startTime":"0","endTime":"0","summary":"07月22日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点42分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.53%，报988.410点。从个股上来看，该概念的成分股中，微芯生物涨1.27%，福瑞股份、天士力、诺泰生物涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为695.99万，其中迈瑞医疗受到资金热捧，主力净流入756.76万；拉长时间线来看，该板块近20日主力资金净流入-12.83亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722094224941f8f7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722094224941f8f7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2452444475","title":"微芯生物(688321.SH)：西格列他钠联合二甲双胍治疗2型糖尿病适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452444475","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452444475?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:00","pubTimestamp":1721379642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)公告，公司全资子公司成都微芯药业有限公司(简称“成都微芯”)收到国家药品监督管理局核准签发的《药品注册证书》，同意批准成都微芯申报的西格列他钠片增加适应症，新增适应症为“与盐酸二甲双胍联合使用：在单独使用盐酸二甲双胍血糖控制不佳时，本品可与盐酸二甲双胍联合使用，配合饮食和运动改善成人2型糖尿病患者的血糖控制”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2452467691","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452467691","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452467691?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:52","pubTimestamp":1721267538,"startTime":"0","endTime":"0","summary":"07月18日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点52分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.72%，报972.240点。从个股上来看，该概念的成分股中，微芯生物跌2.07%，福瑞股份、众生药业、诺泰生物跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-659.10万，其中诺泰生物受到资金热捧，主力净流入166.85万；拉长时间线来看，该板块近20日主力资金净流入-15.24亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180952189681ddf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180952189681ddf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076","688321"],"gpt_icon":0},{"id":"2451656796","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，康弘药业跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451656796","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451656796?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:22","pubTimestamp":1721010153,"startTime":"0","endTime":"0","summary":"07月15日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至10点22分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌2.02%，报969.530点。从个股上来看，该概念的成分股中，康弘药业跌5.10%，福瑞股份、微芯生物、众生药业跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-3833.63万，其中微芯生物受到资金热捧，主力净流入-30.88万；拉长时间线来看，该板块近20日主力资金净流入-15.34亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715102233941f6f27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715102233941f6f27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0239","BK0197","002773","688321"],"gpt_icon":0},{"id":"2450590877","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450590877","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450590877?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:12","pubTimestamp":1720663945,"startTime":"0","endTime":"0","summary":"07月11日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至10点12分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨1.03%，报979.720点。从个股上来看，该概念的成分股中，微芯生物涨3.66%，众生药业、华东医药、天士力涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为1352.73万，其中康弘药业受到资金热捧，主力净流入1123.06万；拉长时间线来看，该板块近20日主力资金净流入-18.93亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101225aef91ac8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101225aef91ac8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2450718268","title":"北向资金7月10日净卖出微芯生物3.58万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450718268","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450718268?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:30","pubTimestamp":1720661441,"startTime":"0","endTime":"0","summary":"7月10日，北向资金减持微芯生物3.58万股连续3日减持。截止当日收盘，沪股通共持有微芯生物280.80万股，占流通股0.68%。沪股通减持金额前五个股分别为赛力斯、北汽蓝谷、中国石化、中国铝业、伊利股份。微芯生物近5个交易日下跌0.12%，沪股通累计减持27.59万股；近20个交易日下跌17.88%，沪股通累计减持29.55万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071109360295a2ae2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071109360295a2ae2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2449748588","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌2.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449748588","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449748588?lang=zh_cn&edition=full","pubTime":"2024-07-08 13:00","pubTimestamp":1720414831,"startTime":"0","endTime":"0","summary":"07月08日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至13点00分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌2.01%，报977.030点。从个股上来看，该概念的成分股中，微芯生物跌2.86%，众生药业、华东医药、诺泰生物跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-3940.23万，其中诺泰生物受到资金热捧，主力净流入907.64万；拉长时间线来看，该板块近20日主力资金净流入-16.32亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081300319681a7dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081300319681a7dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321","688076"],"gpt_icon":0},{"id":"2449494002","title":"微芯生物（688321）7月5日主力资金净买入159.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449494002","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449494002?lang=zh_cn&edition=full","pubTime":"2024-07-06 08:12","pubTimestamp":1720224750,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月5日收盘，微芯生物报收于17.12元，上涨5.35%，换手率1.04%，成交量4.23万手，成交额7095.84万元。近5日资金流向一览见下表：微芯生物融资融券信息显示，融资方面，当日融资买入748.7万元，融资偿还703.96万元，融资净买入44.74万元。微芯生物主营业务：为患者提供可承受的、临床亟需的原创新分子实体药物,具备完整的从药物作用靶点发现与确证、先导分子的发现与评价到新药临床开发、产业化、学术推广及销售的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600012996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2449253810","title":"7月5日微芯生物涨5.35%，工银优选对冲灵活配置混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449253810","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449253810?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:15","pubTimestamp":1720167359,"startTime":"0","endTime":"0","summary":"证券之星消息，7月5日微芯生物涨5.35%创60日新低，收盘报17.12元，换手率1.04%，成交量4.23万手，成交额7095.84万元。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为工银优选对冲灵活配置混合发起A。工银优选对冲灵活配置混合发起A目前规模为0.71亿元，最新净值1.0267，较上一交易日上涨0.11%，近一年上涨5.37%。该公募基金现任基金经理为刘子豪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2449307032","title":"微芯生物：西奥罗尼III期试验已结束，目前正在推进Pre-NDA沟通工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2449307032","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449307032?lang=zh_cn&edition=full","pubTime":"2024-07-05 15:54","pubTimestamp":1720166050,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘你好，西奥罗尼三期失败了吗？微芯生物（688321.SH）7月5日在投资者互动平台表示，西奥罗尼III期试验已结束，目前正在推进Pre-NDA沟通工作。(记者 毕陆名)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705155436957af964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705155436957af964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2448415371","title":"微芯生物07月04日主力资金流出10万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448415371","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448415371?lang=zh_cn&edition=full","pubTime":"2024-07-04 15:18","pubTimestamp":1720077519,"startTime":"0","endTime":"0","summary":"07月04日, 微芯生物股价跌2.64%，报收16.25元，成交金额4507万元，换手率0.67%，振幅4.25%，量比0.73。微芯生物今日主力资金净流出10万元，连续7日净流出，上一交易日主力净流出14万元，今日环比减少28.57%。该股近5个交易日下跌9.17%，主力资金累计净流出2427万元；近20日主力资金累计净流出4147万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070415310995739556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070415310995739556&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2448999173","title":"微芯生物：第二季度“微芯转债”转股39股，累计转股4243股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448999173","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448999173?lang=zh_cn&edition=full","pubTime":"2024-07-01 20:13","pubTimestamp":1719835981,"startTime":"0","endTime":"0","summary":"截至2024年6月30日，“微芯转债”累计有人民币约11万元已转换为公司股票，转股数量为4243股，占“微芯转债”转股前公司已发行股份总额的0.001%。2023年1至12月份，微芯生物的营业收入构成为：医药制造业占比98.83%。截至发稿，微芯生物市值为69亿元。道达号“个股趋势”提醒：1. 微芯生物近30日内北向资金持股量增加46.53万股，占流通股比例增加0.12%；2. 近30日内共有1批机构对微芯生物调研，合计调研的机构家数为5家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407012013159eecd3ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407012013159eecd3ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2448935989","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448935989","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448935989?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:41","pubTimestamp":1719798089,"startTime":"0","endTime":"0","summary":"07月01日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点41分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.58%，报1000.230点。从个股上来看，该概念的成分股中，微芯生物跌1.36%，诺泰生物、华东医药、迈瑞医疗跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-1935.90万，其中天士力受到资金热捧，主力净流入7.46万；拉长时间线来看，该板块近20日主力资金净流入-8.82亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701094129af8fe355&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701094129af8fe355&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2448193862","title":"微芯生物6月28日转融通出借成交6100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448193862","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448193862?lang=zh_cn&edition=full","pubTime":"2024-07-01 08:54","pubTimestamp":1719795276,"startTime":"0","endTime":"0","summary":"根据上交所网站显示，6月28日，微芯生物转融通出借成交6100股，期限为10天。据了解，转融通是指证券金融公司将自有或者依法筹集的资金和证券出借给证券公司，以供其办理融资融券业务的经营活动。上交所接受借入人借入申报的时间为每个交易日 9:15 至 11:30、13:00 至 15:10。公开资料显示，微芯生物法人代表为XIANPING LU，公司注册资本4.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407010854489ee8d583&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407010854489ee8d583&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2447066179","title":"微芯生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2447066179","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447066179?lang=zh_cn&edition=full","pubTime":"2024-06-29 12:32","pubTimestamp":1719635542,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日深圳微芯生物科技股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来深圳微芯生物科技股份有限公司新申请注册商标3件，截止目前公司共持有注册商标88件，另有7件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900013670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2447669901","title":"深圳微芯生物科技股份有限公司注册资本(金)变更发生变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2447669901","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447669901?lang=zh_cn&edition=full","pubTime":"2024-06-29 11:33","pubTimestamp":1719631992,"startTime":"0","endTime":"0","summary":"金融界6月29日消息，据公开信息显示，深圳微芯生物科技股份有限公司近日发生工商变更，公司注册资本由41072.05，156万元变为40853.999，156万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062911411695e75a6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062911411695e75a6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2447640655","title":"微芯生物公布国际专利申请：“一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2447640655","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447640655?lang=zh_cn&edition=full","pubTime":"2024-06-29 05:37","pubTimestamp":1719610631,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示微芯生物公布了一项国际专利申请，专利名为“一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用”，专利申请号为PCT/CN2023/140709，国际公布日为2024年6月27日。专利详情如下：图片来源：世界知识产权组织今年以来微芯生物已公布的国际专利申请4个，较去年同期增加了100%。结合公司2023年年报财务数据，2023年公司在研发方面投入了2.7亿元，同比增65.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900011008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","stockEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.1055},{"period":"3month","weight":-0.1501},{"period":"6month","weight":-0.0113},{"period":"1year","weight":-0.195},{"period":"ytd","weight":-0.2005}],"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","perCapita":"19281股","boardName":"医药制造业","registeredCapital":"40779万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。","serverTime":1721730695947,"listedPrice":20.43,"stockholders":"21150人(较上一季度减少1.25%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}